Reaktionsgleichung
Cl[CH2:2][CH2:3][C:4]1[CH:9]=[CH:8][C:7]([NH:10][C:11](=[O:13])[CH3:12])=[C:6]([CH3:14])[CH:5]=1.Cl.[N:16]1([C:22]2[C:30]3[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=3)[NH:24][N:23]=2)[CH2:21][CH2:20][NH:19][CH2:18][CH2:17]1>>[NH:24]1[C:25]2[C:30](=[CH:29][CH:28]=[CH:27][CH:26]=2)[C:22]([N:16]2[CH2:17][CH2:18][N:19]([CH2:2][CH2:3][C:4]3[CH:9]=[CH:8][C:7]([NH:10][C:11](=[O:13])[CH3:12])=[C:6]([CH3:14])[CH:5]=3)[CH2:20][CH2:21]2)=[N:23]1Komponenten
3
Versuchsvorschrift
Starting with N-[4-(2-chloro-ethyl)-2-methyl-phenyl]-acetamide (0.194 g, 0.915 mmol) and 3-piperazin-1-yl-1H-indazole hydrochloride (0.328 g, 1.372 mmol), and following the procedure outlined in Example 501, N-(4-{2-[4-(1H-indazol-3-yl)-piperazin-1-yl]-ethyl}-2-methyl-phenyl)-acetamide was obtained as its hydrochloride salt (0.038 g, 0.101 mmol).
Quellen und Nachweise
- ORD-Eintrag
- ord-4c381a7fc2604d56818c0c46585e55e5
- Quelldatensatz
- uspto-grants-2006_09
- Patentnummer
- US07101886B2
Verknüpfte Notizen
Wird geladen…